This Article Full Text Full Text (PDF) CME: Take the course for this article: Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Bl... eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ribas, A. Articles by Gomez-Navarro, J. Search for Related Content PubMed PubMed Citation Articles by Ribas, A. Articles by Gomez-Navarro, J.

Melanoma and Cutaneous Malignancies

Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer

^aDepartment of Medicine, Division of Hematology/Oncology, ^bDepartment of Surgery, Division of Surgical Oncology, and ^cJonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California, USA; Departments of ^dImmunology, ^eClinical PK/PD, ^gDrug Safety R&D, and ^fClinical Oncology, Pfizer Global Research & Development, Groton-New London, Connecticut, USA; ^hUniversity of Rochester School of Medicine and Dentistry, Rochester, New York, USA

Key Words. CTLA-4 • Melanoma • T cell • Antitumor

Correspondence: Correspondence: Jesus Gomez-Navarro, M.D., Pfizer Global Research & Development, Groton-New London, Connecticut 06340, USA. Telephone: 860-732-2079; Fax: 860-732-7127; e-mail: jesus.gomez-navarro{at}pfizer.com

Tremelimumab (CP-675,206) is a fully human monoclonal antibody specific for human cytotoxic T lymphocyte–associated antigen 4 (CTLA-4, CD152) in clinical development for patients with cancer. Blocking the CTLA-4 negative costimulatory receptor with the antagonistic antibody tremelimumab results in immune activation. Administration of tremelimumab to patients with locally advanced and metastatic melanoma has resulted in a subset of patients with durable objective tumor regressions. Its IgG₂ isotype minimizes the possibility of cytotoxic effects on activated T lymphocytes and cytokine release syndrome. Preclinical testing in vitro and in large animal models predicted the target concentrations of circulating antibody in humans necessary for a pharmacodynamic effect. Phase I clinical trials provided evidence of dose- or exposure-related effects consistent with the anticipated mechanism of action. Further clinical development has led to two ongoing registration trials in patients with metastatic melanoma: a phase III randomized trial of tremelimumab versus dacarbazine or temozolomide in previously untreated patients with advanced melanoma and a phase II trial of tremelimumab in previously treated patients with advanced melanoma.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				C. Menard, F. Ghiringhelli, S. Roux, N. Chaput, C. Mateus, U. Grohmann, S. Caillat-Zucman, L. Zitvogel, and C. Robert CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab? Clin. Cancer Res., August 15, 2008; 14(16): 5242 - 5249. [Abstract] [Full Text] [PDF]

				J. Begley and A. Ribas Targeted Therapies to Improve Tumor Immunotherapy Clin. Cancer Res., July 15, 2008; 14(14): 4385 - 4391. [Abstract] [Full Text] [PDF]

				O. J. Finn Cancer Immunology N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715. [Full Text] [PDF]